[
  {
    "id": 31,
    "question": "Case scenario about Weber's syndrome, where is the lesion?",
    "option_a": "Midbrain basis",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nWeber's syndrome is a classic brainstem stroke syndrome that involves the midbrain. It is characterized by an ipsilateral oculomotor nerve (CN III) palsy and contralateral hemiparesis, making localization of the lesion to the midbrain crucial.\n\n**Pathophysiology**\n\nA lesion at the level of the midbrain basis (specifically in the cerebral peduncle region) can compromise both the oculomotor nerve fibers and the corticospinal tracts. Infarctions in this area typically result from occlusion of perforating branches of the posterior cerebral or superior cerebellar arteries.\n\n**Clinical Correlation**\n\nClinically, patients present with a combination of ipsilateral ptosis, pupil dilation, and eye movement deficits along with contralateral weakness/hemiparesis. This pattern allows for precise neuroanatomic localization, linking clinical findings to a lesion in the midbrain.\n\n**Diagnostic Approach**\n\nDiagnosis is primarily based on clinical examination supported by neuroimaging (MRI) which can confirm an infarct in the midbrain. Differential diagnoses include other brainstem syndromes (e.g., Benedikt's syndrome, Claude's syndrome) which have differing clinical features depending on the exact anatomic involvement.\n\n**Management Principles**\n\nManagement is generally supportive and follows standard ischemic stroke protocols including antiplatelet therapy, management of risk factors, and rehabilitation. In the setting of acute stroke, thrombolytic therapy may be considered if the patient meets criteria. In pregnancy and lactation, the choice of thrombolytic agents and supportive medications should be made with fetal/infant safety in mind.\n\n**Option Analysis**\n\nOption A (midbrain basis) is correct because Weber's syndrome is caused by infarction or a lesion in the ventral midbrain. Other choices, if provided, would likely refer to non-matching locations (e.g., pons, thalamus) and are therefore incorrect.\n\n**Clinical Pearls**\n\n1. Weber's syndrome is a midbrain stroke characterized by ipsilateral third nerve palsy and contralateral hemiparesis. 2. The lesion is located in the ventral midbrain (basis pedunculi). 3. Differential diagnosis should include other midbrain syndromes which may have overlapping yet distinct features.\n\n**Current Evidence**\n\nCurrent neuroimaging modalities, especially high-resolution MRI, continue to assist in the rapid localization and confirmation of brainstem strokes linked to syndromes like Weber's. Updated stroke guidelines underscore the importance of swift diagnosis and management.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "id": 32,
    "question": "A case of acute ischemic stroke, BP is 193/103, what to do next?",
    "option_a": "IV labetalol",
    "option_b": "IV nitroprusside",
    "option_c": "Observation",
    "option_d": "Resume home medications",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nIn the setting of acute ischemic stroke, elevated blood pressure is common and is part of the body\u2019s physiological response to maintain cerebral perfusion. Management of blood pressure is nuanced and depends on whether the patient is eligible for reperfusion therapies.\n\n**Pathophysiology**\n\nAfter an ischemic stroke, autoregulation of cerebral blood flow is impaired, and permissive hypertension helps support penumbral tissue. Aggressive blood pressure reduction can potentially worsen ischemia in the affected areas.\n\n**Clinical Correlation**\n\nA patient who presents with an acute ischemic stroke and a blood pressure of 193/103 mm Hg falls within the range tolerated in patients not eligible for thrombolytic therapy. If the patient is not undergoing reperfusion treatment, the elevated blood pressure is typically not immediately lowered unless it exceeds thresholds (commonly 220/120 mm Hg).\n\n**Diagnostic Approach**\n\nBlood pressure management in stroke is guided by clinical criteria and imaging findings. Differential considerations include hemorrhagic stroke (where blood pressure control is more aggressive) versus ischemic stroke. In ischemic stroke, neuroimaging (CT/MRI) distinguishes between these conditions and directs management.\n\n**Management Principles**\n\nFor ischemic stroke patients not receiving thrombolytic therapy, current guidelines recommend tolerating higher blood pressures (up to 220/120 mm Hg)\u2014this is known as permissive hypertension. If the patient were eligible for IV tPA, blood pressure would need to be lowered to below 185/110 mm Hg using agents like IV labetalol before therapy. In pregnancy, blood pressure management must consider maternal and fetal safety, with agents like labetalol and hydralazine often preferred; however, if the stroke is not treated with thrombolysis, similar permissive limits may apply under close monitoring.\n\n**Option Analysis**\n\nOption A (IV labetalol) would be indicated if the patient were a candidate for thrombolysis, as the blood pressure would need to be reduced to a safe level (<185/110 mm Hg). Option B (IV nitroprusside) is not typically used in acute ischemic stroke due to its potent and unpredictable effects on cerebral blood flow. Option C (Observation) is correct in a scenario where the patient is not receiving reperfusion therapy because the blood pressure is within the acceptable range for permissive hypertension. Option D (Resume home medications) is nonspecific and does not directly address the acute management of blood pressure in a stroke setting.\n\n**Clinical Pearls**\n\n1. Permissive hypertension (up to 220/120 mm Hg) is generally allowed in acute ischemic stroke patients who are not candidates for reperfusion therapy. 2. For patients eligible for IV tPA, blood pressure must be carefully lowered to below 185/110 mm Hg before administration. 3. Monitoring and gradual reduction, when indicated, minimize the risk of compromising cerebral perfusion.\n\n**Current Evidence**\n\nRecent guidelines continue to support a conservative approach to blood pressure management in acute ischemic stroke for non-thrombolysis candidates. There is ongoing research into optimal blood pressure targets during the hyperacute phase of stroke, balancing the risks of recurrent ischemia against the potential harms of aggressive blood pressure lowering.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "id": 33,
    "question": "Patient has recurrent headache and TIAs, he did cerebral angio which showed the following, what is the most likely diagnosis?",
    "option_a": "",
    "option_b": "(assumed to be Moyamoya disease) is correct if the angiography reveals progressive stenosis of the terminal internal carotid arteries with prominent collateral vessels. Other options can be excluded as follows: \u2022 Atherosclerosis typically shows focal stenosis in older individuals. \u2022 Arterial dissection would present acutely with a tear, often along the cervical vessels. \u2022 Vasculitis tends to have systemic inflammatory markers and multifocal segmental narrowing. \u2022 Fibromuscular dysplasia classically displays a 'string\u2010of\u2010beads' pattern rather than the \u201cpuff\u2010of\u2010smoke\u201d appearance.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nThis question asks you to identify an arteriopathy on cerebral angiography in a patient with recurrent headaches and transient ischemic attacks (TIAs). In such cases, several vascular conditions (e.g., atherosclerosis, dissection, vasculitis, fibromuscular dysplasia, and Moyamoya disease) are considered; the key lies in recognizing characteristic imaging patterns.\n\n**Pathophysiology**\n\nMoyamoya disease is characterized by progressive stenosis of the distal internal carotid arteries and their proximal branches. In response to the reduced blood flow, a network of transdural collateral vessels develops. On angiography, these collaterals appear as a hazy \u201cpuff\u2010of\u2010smoke\u201d pattern. This abnormal vasculature predisposes patients to recurrent TIAs and strokes, and headache is a common accompanying symptom.\n\n**Clinical Correlation**\n\nPatients may present with recurrent transient neurological deficits (TIAs) and headaches. Although Moyamoya is classically described in children, it also occurs in young to middle\u2010aged adults and may have variable presentations including ischemic or hemorrhagic strokes.\n\n**Diagnostic Approach**\n\nCerebral angiography remains the gold standard. Differential diagnoses include: \u2022 Large artery atherosclerosis (typically seen in older patients with classic risk factors) \u2022 Arterial dissection (often with an intimal flap or double lumen appearance) \u2022 Vasculitis (with segmental narrowing and beading, often accompanied by systemic signs) \u2022 Fibromuscular dysplasia (showing a \u201cstring\u2010of\u2010beads\u201d pattern). The pattern of progressive stenosis with the development of a network of abnormal collateral vessels helps differentiate Moyamoya.\n\n**Management Principles**\n\nThe first\u2010line management for symptomatic Moyamoya disease is surgical revascularization (either direct, such as superficial temporal artery to middle cerebral artery bypass, or indirect techniques). Medical management (including antiplatelet agents) is mainly supportive. In pregnant or lactating women, the decision for surgical intervention is individualized, with careful coordination between neurosurgery, obstetrics, and neurology to minimize fetal radiation exposure and optimize maternal outcomes.\n\n**Option Analysis**\n\nAlthough the exact options are not provided, the differential includes several entities. Option B (assumed to be Moyamoya disease) is correct if the angiography reveals progressive stenosis of the terminal internal carotid arteries with prominent collateral vessels. Other options can be excluded as follows: \u2022 Atherosclerosis typically shows focal stenosis in older individuals. \u2022 Arterial dissection would present acutely with a tear, often along the cervical vessels. \u2022 Vasculitis tends to have systemic inflammatory markers and multifocal segmental narrowing. \u2022 Fibromuscular dysplasia classically displays a 'string\u2010of\u2010beads' pattern rather than the \u201cpuff\u2010of\u2010smoke\u201d appearance.\n\n**Clinical Pearls**\n\n\u2022 Moyamoya means 'puff\u2010of\u2010smoke' in Japanese \u2013 a reference to its characteristic angiographic appearance. \u2022 Recurrent TIAs and headaches in a younger patient should prompt consideration of Moyamoya, especially when imaging shows extensive collateralization. \u2022 Differentiating Moyamoya from other arteriopathies is crucial since surgical revascularization can significantly improve outcomes.\n\n**Current Evidence**\n\nRecent literature supports early surgical revascularization for symptomatic Moyamoya disease to reduce the risk of stroke. The updated guidelines emphasize the importance of high\u2010quality vascular imaging for diagnosis and advocate for a multidisciplinary approach to management, including considerations during pregnancy where imaging and surgical timing are carefully planned.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "id": 34,
    "question": "82-year-old woman came with acute ischemic stroke (2 hours onset) with partial improvement of her deficit?",
    "option_a": "Give IV tPA",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nThis question deals with the management of acute ischemic stroke in an elderly patient who shows partial improvement early in the time window. The decision to administer intravenous thrombolysis (IV tPA) depends on the severity and functional impact of the residual deficits.\n\n**Pathophysiology**\n\nAcute ischemic stroke results from an occlusion of a cerebral vessel leading to ischemia of the brain tissue. In some patients, spontaneous recanalization or the natural evolution of the thrombus can result in partial clinical improvement. However, the risk of hemorrhagic transformation with thrombolytic therapy remains, and the net benefit must be weighed based on the disability of the remaining deficits.\n\n**Clinical Correlation**\n\nAn 82\u2010year-old patient may present with stroke symptoms that begin to improve spontaneously. The key consideration is whether the residual deficits are disabling. \u2018Rapid improvement\u2019 or minimal deficits might suggest that the risks of IV tPA (notably intracranial hemorrhage) may outweigh the benefits.\n\n**Diagnostic Approach**\n\nA thorough neurological exam, often quantified by the NIH Stroke Scale (NIHSS), is used to determine the severity of stroke. Differential considerations include a transient ischemic attack (TIA) versus a minor stroke. Brain imaging (CT/MRI) is also used to rule out hemorrhage before considering IV tPA.\n\n**Management Principles**\n\nFor patients within 4.5 hours of onset with disabling deficits, IV tPA remains the first\u2010line treatment. However, in patients with mild or rapidly improving symptoms that are deemed non\u2010disabling, the benefit of IV tPA is less clear. In such cases, supportive care and observation may be preferred. In pregnant or lactating patients, the use of IV tPA is considered when the benefits significantly outweigh the risks, with careful monitoring and adjustments to minimize potential adverse effects.\n\n**Option Analysis**\n\n\u2022 Option A (Give IV tPA) is the standard for acute ischemic strokes with significant, disabling deficits. However, in this scenario the patient shows partial improvement, suggesting that the deficit may now be minor or non\u2010disabling. \u2022 Option B (the marked answer) is assumed to represent conservative management (i.e., withholding IV tPA) when the residual deficit is not clinically disabling. Given the ambiguity in the clinical improvement, many clinicians choose not to expose patients to the risk of hemorrhage if the deficit is minimal. Thus, the marked answer is appropriate provided that the residual deficit is indeed non\u2010disabling.\n\n**Clinical Pearls**\n\n\u2022 Always assess the degree of residual disability \u2013 even if a patient shows some improvement, a significant functional impairment warrants thrombolysis. \u2022 There is no strict age cutoff for IV tPA; decisions should be based on the balance of risks and benefits. \u2022 \u2018Rapid improvement\u2019 does not automatically preclude treatment, but if the symptoms are minor and not disabling, observation may be appropriate.\n\n**Current Evidence**\n\nRecent studies have highlighted that patients with minor or rapidly improving symptoms often do well with conservative management, though it is recognized that a subset may deteriorate. Current guidelines recommend individualized assessment of disability rather than relying solely on the degree of improvement, with ongoing research into objective measures to guide thrombolytic use in this group.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "id": 35,
    "question": "Patient developed ischemic stroke, his echo showed intracardiac thrombus as part of stroke work up what is the best option for secondary prevention of stroke?",
    "option_a": "Warfarin",
    "option_b": "NOACs",
    "option_c": "Aspirin",
    "option_d": "Clopidogrel",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nThis question focuses on the secondary prevention of cardioembolic stroke in a patient whose workup (via echocardiography) revealed an intracardiac thrombus. The prevention strategy in such settings is aimed at reducing further embolic events.\n\n**Pathophysiology**\n\nAn intracardiac thrombus, often formed in areas of regional akinesis or dyskinesis (such as post-myocardial infarction), can dislodge and embolize to the cerebral circulation, causing ischemic stroke. Anticoagulants decrease thrombin production and clot propagation, thereby reducing embolic risk.\n\n**Clinical Correlation**\n\nPatients with cardioembolic strokes typically present with sudden onset focal neurological deficits. Echocardiography is used to identify intracardiac sources of emboli. The discovery of a thrombus mandates anticoagulation to prevent recurrent embolization.\n\n**Diagnostic Approach**\n\nOnce a stroke is identified, workup includes brain imaging to identify the ischemic territory and cardiac imaging (transthoracic or transesophageal echo) to evaluate for intracardiac thrombi. Differential diagnoses include atherosclerotic stroke (where antiplatelet therapy is preferred) and paradoxical emboli (which may require further investigation for a patent foramen ovale).\n\n**Management Principles**\n\nFor secondary prevention in patients with a documented intracardiac thrombus, anticoagulation is the cornerstone. Warfarin (a vitamin K antagonist) has been the traditional first-line agent, given its proven efficacy in preventing systemic embolization. Novel oral anticoagulants (NOACs) are used in non-valvular atrial fibrillation, but their use in patients with intracardiac thrombus has less robust evidence. In pregnant patients, warfarin is contraindicated, particularly in the first trimester due to fetal teratogenicity; low molecular weight heparin is preferred during pregnancy and lactation.\n\n**Option Analysis**\n\n\u2022 Option A (Warfarin) is correct because it effectively prevents thrombus propagation in patients with intracardiac thrombus. \u2022 Option B (NOACs) are currently less established for this specific indication despite their success in atrial fibrillation. \u2022 Options C (Aspirin) and D (Clopidogrel) are antiplatelet agents that do not adequately address the risk of thromboembolism from an intracardiac clot.\n\n**Clinical Pearls**\n\n\u2022 Always evaluate for an intracardiac source in stroke patients when indicated, as management differs significantly from atherosclerotic stroke. \u2022 Warfarin remains the first-line anticoagulant for confirmed intracardiac thrombus unless contraindicated. \u2022 In women of childbearing age or those who are pregnant/lactating, consider alternative anticoagulation strategies.\n\n**Current Evidence**\n\nRecent guidelines reaffirm the role of warfarin for patients with intracardiac thrombus. Although NOACs have become popular for non-valvular atrial fibrillation, their role in intracardiac thrombus is less clear, and ongoing trials seek to clarify their safety and efficacy in this indication.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "id": 36,
    "question": "Sickle cell disease patient developed ischemic stroke, what to do as secondary prevention?",
    "option_a": "Chronic blood transfusion (from AHA/ASA 2021 guidelines for secondary prevention of stroke)",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nIn patients with sickle cell disease (SCD), the risk of ischemic stroke is significantly elevated due to abnormal red blood cell morphology causing vaso-occlusion and endothelial damage. Secondary prevention strategies focus on reducing the proportion of sickled cells to prevent further vascular occlusion.\n\n**Pathophysiology**\n\nSickle cells have altered rheological properties and can occlude small cerebral vessels. Chronic transfusion therapy dilutes the concentration of hemoglobin S (HbS) in the circulation, thereby decreasing the likelihood of sickling and subsequent vaso-occlusion. This reduction in HbS minimizes endothelial injury and reduces the risk of recurrent stroke.\n\n**Clinical Correlation**\n\nPatients with SCD who have already suffered an ischemic stroke are at high risk for recurrence. Clinical management involves aggressive intervention to lower HbS levels. Chronic blood transfusions have been shown to reduce this risk effectively.\n\n**Diagnostic Approach**\n\nWorkup includes brain imaging to confirm ischemia along with laboratory evaluation of hemoglobin electrophoresis. Transcranial Doppler ultrasound may also be used for screening in children with SCD to assess stroke risk.\n\n**Management Principles**\n\nFor secondary stroke prevention in SCD, chronic red blood cell transfusion is considered the first-line therapy (as recommended by the AHA/ASA 2021 guidelines). The goal is to maintain HbS levels below 30% to minimize the risk of further vaso-occlusive events. Hydroxyurea is another therapy that can reduce sickling and is often used in conjunction with supportive measures. In pregnant or lactating patients with SCD, transfusion protocols require careful coordination to avoid alloimmunization and iron overload, and multidisciplinary care is essential.\n\n**Option Analysis**\n\n\u2022 Option A (Chronic blood transfusion) is the recommended strategy for secondary stroke prevention in patients with SCD. \u2022 Other options (though not detailed here) such as antiplatelet agents are less effective in modifying the underlying sickling process.\n\n**Clinical Pearls**\n\n\u2022 In SCD, prevention of stroke centers on reducing the hemoglobin S percentage \u2013 keeping it below 30% is crucial. \u2022 Regular transfusions, while effective, necessitate monitoring for iron overload and may require chelation therapy. \u2022 Multidisciplinary management is key, especially in patients who are pregnant or lactating.\n\n**Current Evidence**\n\nThe latest AHA/ASA guidelines (2021) strongly advocate for chronic transfusion therapy for secondary stroke prevention in SCD patients. Emerging research is also evaluating the role of gene therapy and other novel agents, but transfusion remains the standard of care at present.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "id": 37,
    "question": "Scenario with picture of AVM, which of the following is a risk factor for bleeding?",
    "option_a": "Previous history of bleeding",
    "option_b": "Deep AVM",
    "option_c": "Deep venous drain",
    "option_d": "Presence of aneurysm",
    "option_e": "Highest grade with size",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nArteriovenous malformations (AVMs) are congenital vascular anomalies composed of a tangle of abnormal vessels with direct arteriovenous shunting. One of the key clinical concerns in AVMs is the risk of hemorrhage. A previous history of bleeding is recognized as an important predictor for future hemorrhagic events because it suggests vessel wall instability.\n\n**Pathophysiology**\n\nAVMs have an abnormal architecture lacking the normal capillary bed, leading to high-flow, high-pressure shunts. A prior hemorrhage indicates that the fragile, dysplastic vessels have already ruptured once, thereby increasing the likelihood of rebleeding. The hemodynamic stress and turbulent flow further predispose to weakening and rupture of adjacent vessel segments. This concept is supported by studies showing that prior hemorrhage is the strongest predictor for subsequent bleeding.\n\n**Clinical Correlation**\n\nClinically, patients with a history of AVM-related hemorrhage are at heightened risk for rebleeding, which may result in sudden neurological deterioration, headache, or focal deficits. Recognition of this risk emphasizes the need for close monitoring and often an aggressive therapeutic approach.\n\n**Diagnostic Approach**\n\nThe diagnosis and risk stratification of AVMs involve neuroimaging. Digital subtraction angiography (DSA) remains the gold standard, though CT/MR angiography can provide valuable information regarding the nidus, venous drainage, and any associated aneurysms. Differential diagnoses include cavernous malformations (which typically present with smaller, \u2018popcorn-like\u2019 lesions and less aggressive hemorrhagic risk) and capillary telangiectasias.\n\n**Management Principles**\n\nThe management of AVMs with a history of hemorrhage is challenging. First-line options include microsurgical resection, endovascular embolization, and stereotactic radiosurgery, often used in combination. Decision making is based on AVM location, size, venous drainage, and patient-specific factors. In pregnancy or lactation, noninvasive modalities and careful consideration of radiation exposure are paramount, with embolization using newer materials sometimes preferred if intervention is urgent. Multidisciplinary discussion is essential in these scenarios.\n\n**Option Analysis**\n\nOption A (Previous history of bleeding) is correct because a prior hemorrhage is the most consistent predictor for subsequent AVM rupture. Option B (Deep AVM) and Option C (Deep venous drainage) are also associated with higher hemorrhagic risk but are not as strongly predictive as a history of bleeding. Option D (Presence of aneurysm) is a recognized risk factor, particularly with intranidal aneurysms, and Option E (Highest grade with size) can be associated with increased risk, but the literature most strongly supports previous hemorrhage as the most significant risk factor.\n\n**Clinical Pearls**\n\n\u2022 A prior hemorrhagic event in AVM patients greatly increases the risk of rebleeding. \u2022 Deep location and deep venous drainage also elevate hemorrhage risk. \u2022 Multimodality imaging is crucial for risk stratification and management planning.\n\n**Current Evidence**\n\nRecent studies and guideline updates continue to support previous hemorrhage as a key risk factor for AVM bleeding. Research is ongoing into the molecular and hemodynamic factors that predispose certain AVMs to rebleed, and treatment algorithms are increasingly tailored to individual hemorrhagic risk profiles, especially when managing high-risk lesions in special populations such as pregnant or lactating patients.",
    "exam_year": "2018",
    "exam_type": "Part I",
    "image_url": "page_6.png"
  },
  {
    "id": 38,
    "question": "Pt with muscle weakness, optic atrophy, hearing loss, family history of similar condition:",
    "option_a": "SCA 7",
    "option_b": "SCA 6",
    "option_c": "Friedrich ataxia",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nSpinocerebellar ataxia type 7 (SCA7) is one of several autosomal dominant cerebellar ataxias characterized by progressive neurodegeneration. Unlike many other SCAs, SCA7 uniquely presents with visual impairment due to retinal degeneration, often accompanied by optic atrophy and sometimes hearing loss, which is a result of widespread neurodegeneration.\n\n**Pathophysiology**\n\nSCA7 is caused by a CAG trinucleotide repeat expansion in the ATXN7 gene leading to an abnormally long polyglutamine tract within the ataxin-7 protein. This abnormal protein misfolds and aggregates, causing neuronal dysfunction and cell death particularly in the cerebellum, brainstem, and retina. The degeneration of retinal photoreceptors leads to pigmentary retinopathy and subsequent optic nerve atrophy.\n\n**Clinical Correlation**\n\nPatients with SCA7 typically present with progressive cerebellar ataxia along with visual impairment, which may initially manifest as blurry vision or difficulty with central vision, eventually leading to optic atrophy. Hearing loss can also occur as a less common but noted feature. A positive family history supports the diagnosis of an autosomal dominant disorder.\n\n**Diagnostic Approach**\n\nThe diagnosis is established by clinical examination, family history, and confirmation via genetic testing for the ATXN7 gene repeat expansion. Differential diagnoses include SCA6, which generally presents with a more pure cerebellar ataxia without significant retinal involvement, and Friedreich ataxia (which is autosomal recessive and more commonly features cardiomyopathy and peripheral neuropathy rather than optic atrophy).\n\n**Management Principles**\n\nThere is currently no cure for SCA7; management is supportive and focuses on symptom relief and rehabilitation. Physical therapy, occupational therapy, and speech therapy are key components of care. Genetic counseling is essential for affected families. In pregnant or lactating patients, special care should be taken regarding medications that may exacerbate neurological symptoms, and genetic counseling is crucial in family planning.\n\n**Option Analysis**\n\nOption A (SCA 7) is correct as it best fits the clinical picture of progressive ataxia combined with optic atrophy and hearing loss. Option B (SCA 6) is primarily associated with cerebellar ataxia without significant retinal or optic pathway involvement. Option C (Friedreich ataxia) typically presents earlier in life with ataxia, cardiomyopathy, and diabetes, and follows an autosomal recessive inheritance pattern. The blank Option D provides no diagnostic value.\n\n**Clinical Pearls**\n\n\u2022 Visual impairment (often from retinal degeneration) is a hallmark of SCA7. \u2022 A positive family history with autosomal dominant inheritance should prompt consideration of SCA7. \u2022 Genetic testing is definitive in distinguishing between different SCAs.\n\n**Current Evidence**\n\nRecent advances in molecular genetics have improved early diagnosis of SCA7. Although no disease-modifying therapies currently exist, ongoing research into polyglutamine disorders holds promise for targeted therapies. Updated guidelines stress the importance of multidisciplinary management and genetic counseling, particularly for women in their childbearing years.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "id": 39,
    "question": "Young male coming with early dementia and bilateral LL weakness, has brothers who are similarly affected, MRI showed diffuse white matter lesions what is the diagnosis:",
    "option_a": "Adrenoleukodystrophy.",
    "option_b": "Hereditary spastic paraplegia.",
    "option_c": "Krabbe disease",
    "option_d": "Tangier disease",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nAdrenoleukodystrophy (ALD) is a peroxisomal disorder characterized by the accumulation of very long chain fatty acids (VLCFAs), leading to progressive demyelination of the white matter and adrenal insufficiency. It is typically inherited in an X-linked manner, which explains its prevalence in young males and its occurrence among affected brothers.\n\n**Pathophysiology**\n\nThe defect in ALD lies in the ABCD1 gene, which impairs the transport of VLCFAs into peroxisomes for beta-oxidation. The resultant accumulation of these fatty acids disrupts membrane integrity and causes inflammatory demyelination in the central nervous system. The adrenal cortex is similarly affected, leading to adrenal insufficiency in many patients.\n\n**Clinical Correlation**\n\nYoung males with ALD often present with behavioral changes, cognitive decline (early dementia), and motor dysfunction such as spastic paraparesis (which may manifest as bilateral lower limb weakness). MRI typically reveals diffuse, often parieto-occipital, white matter lesions. A family history positive for similar neurological impairment heightens the suspicion of ALD.\n\n**Diagnostic Approach**\n\nDiagnosis is based on clinical presentation, neuroimaging (with MRI showing symmetric white matter changes), and biochemical assays showing elevated VLCFA levels, followed by genetic testing for confirmation. Differential diagnoses include hereditary spastic paraplegia (which typically lacks significant white matter changes and cognitive decline), Krabbe disease (which presents in infancy), and Tangier disease (which has distinct lipid abnormalities and lacks the neurological pattern seen in ALD).\n\n**Management Principles**\n\nThe management of ALD includes hormone replacement for adrenal insufficiency and consideration of hematopoietic stem cell transplantation (HSCT) in early cerebral disease to slow progression of demyelination. Emerging gene therapies are under investigation. In pregnant patients, counseling and careful endocrine management are critical, while lactation requires attention to the safety of any medications used (for instance, continuing hydrocortisone replacement as indicated).\n\n**Option Analysis**\n\nOption A (Adrenoleukodystrophy) is correct because the clinical picture of early dementia, bilateral lower limb weakness, diffuse white matter lesions on MRI, and a positive family history in a young male strongly fits ALD. Option B (Hereditary spastic paraplegia) usually lacks the white matter changes and cognitive decline. Option C (Krabbe disease) typically presents in infancy with rapid neurodegeneration, and Option D (Tangier disease) is primarily a lipid metabolism disorder without the described neuroimaging findings.\n\n**Clinical Pearls**\n\n\u2022 ALD is an X-linked peroxisomal disorder that primarily affects young males. \u2022 Elevated VLCFA levels are key to the diagnosis. \u2022 Early intervention with HSCT may slow cerebral progression if undertaken before significant neurological decline.\n\n**Current Evidence**\n\nRecent studies emphasize the importance of early detection via newborn screening programs and the potential role of emerging gene therapies and HSCT. Current guidelines outline a multidisciplinary approach for managing neurologic and endocrine aspects of ALD, with special considerations for counseling women at risk during pregnancy.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "id": 40,
    "question": "What is the mechanism of stroke in dissection?",
    "option_a": "",
    "option_b": ") is assumed to represent the mechanism of stroke via thrombus formation and subsequent embolization from the dissection site. This is the accepted pathophysiological mechanism in most cases of cervical artery dissection. Other potential answers may have described hemodynamic compromise or direct occlusion, but evidence favors an embolic mechanism as the predominant cause of ischemic stroke in dissection.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nArterial dissection involves a tear in the intimal layer of the vessel wall. This creates a false lumen where blood can accumulate, leading to an intramural hematoma. The process can result in luminal narrowing and the formation of thrombi, which may subsequently embolize.\n\n**Pathophysiology**\n\nIn dissection, an intimal tear allows blood to enter the arterial wall, dissecting between layers. This results in an intramural hematoma that can compress the true lumen and cause cerebral ischemia either via hemodynamic insufficiency or, more commonly, through thrombus formation at the site of the tear. Pieces of the thrombus can break off and embolize distally, causing an ischemic stroke.\n\n**Clinical Correlation**\n\nPatients with arterial dissection often present with acute pain (such as neck or head pain) followed by focal neurological deficits due to cerebral ischemia. The embolic mechanism explains the frequently observed multifocal ischemic lesions on imaging. Recognizing the mechanism helps tailor management toward preventing further embolic events.\n\n**Diagnostic Approach**\n\nNoninvasive imaging, including CT angiography and MR angiography, is key in diagnosing arterial dissection by visualizing the double lumen or an intramural hematoma. Differential diagnoses include atherosclerotic stroke, vasculitis, and cardioembolic stroke. Distinguishing features on imaging, such as the elongated dissection flap or tapered occlusion, aid in differentiation.\n\n**Management Principles**\n\nInitial management of arterial dissection is medical, focusing on antithrombotic therapy to prevent thromboembolism. Current guidelines suggest using either antiplatelet or anticoagulant agents with no clear superiority of one over the other in many cases. Endovascular intervention may be considered in patients with persistent symptoms or worsening dissection. In pregnant patients, low-molecular-weight heparin is often preferred over vitamin K antagonists due to safety profiles, and therapy should be closely coordinated with obstetric care. Lactating mothers can typically use antiplatelet agents safely, but the choice of medication should be individualized.\n\n**Option Analysis**\n\nAlthough the specific options are not provided, the marked answer (Option B) is assumed to represent the mechanism of stroke via thrombus formation and subsequent embolization from the dissection site. This is the accepted pathophysiological mechanism in most cases of cervical artery dissection. Other potential answers may have described hemodynamic compromise or direct occlusion, but evidence favors an embolic mechanism as the predominant cause of ischemic stroke in dissection.\n\n**Clinical Pearls**\n\n\u2022 Arterial dissection is a common cause of stroke in young patients and often presents with pain followed by neurological deficits. \u2022 The primary mechanism involves thrombus formation in a false lumen with subsequent embolization. \u2022 Early diagnosis with vascular imaging is crucial in guiding appropriate antithrombotic therapy.\n\n**Current Evidence**\n\nRecent randomized studies have shown similar outcomes between antiplatelet and anticoagulant strategies for cervical artery dissections. Current guidelines emphasize individualized therapy and highlight safety considerations for special populations such as pregnant and lactating women, recommending agents with favorable risk profiles and minimal fetal/neonatal exposure.",
    "exam_year": "2018",
    "exam_type": "Part I"
  }
]